Trial Profile
Influence of Bosentan on the Pharmacokinetics of Nintedanib in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2017
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Bosentan
- Indications Bladder cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Idiopathic pulmonary fibrosis; Liver cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
- 18 Mar 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 16 Feb 2016 New trial record